LAVA Therapeutics (NASDAQ:LVTX) Price Target Increased to $25.00 by Analysts at SVB Leerink

LAVA Therapeutics (NASDAQ:LVTXGet Rating) had its price objective raised by SVB Leerink to $25.00 in a report released on Wednesday, Stock Target Advisor reports. The firm currently has an “outperform” rating on the stock.

Separately, Zacks Investment Research upgraded LAVA Therapeutics from a “strong sell” rating to a “hold” rating in a report on Saturday, April 23rd.

Shares of LVTX traded down $0.23 during trading hours on Wednesday, reaching $3.58. The stock had a trading volume of 7,518 shares, compared to its average volume of 5,782. LAVA Therapeutics has a 12 month low of $3.22 and a 12 month high of $12.92. The firm has a 50-day simple moving average of $4.22 and a 200 day simple moving average of $5.23. The company has a market capitalization of $90.75 million, a price-to-earnings ratio of -0.27 and a beta of 0.46.

A hedge fund recently bought a new stake in LAVA Therapeutics stock. Point72 Asset Management L.P. acquired a new stake in shares of LAVA Therapeutics (NASDAQ:LVTXGet Rating) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm acquired 123,911 shares of the company’s stock, valued at approximately $734,000. Point72 Asset Management L.P. owned approximately 0.49% of LAVA Therapeutics at the end of the most recent quarter. 31.77% of the stock is currently owned by institutional investors and hedge funds.

About LAVA Therapeutics (Get Rating)

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.

Featured Stories

Stock Target Advisor logo

Receive News & Ratings for LAVA Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LAVA Therapeutics and related companies with's FREE daily email newsletter.